Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis.

Maier M, Welt T, Wirth F, Montrasio F, Preisig D, McAfoose J, Vieira FG, Kulic L, Späni C, Stehle T, Perrin S, Weber M, Hock C, Nitsch RM, Grimm J.

Sci Transl Med. 2018 Dec 5;10(470). pii: eaah3924. doi: 10.1126/scitranslmed.aah3924.

PMID:
30518612
2.

Brain interstitial fluid glutamine homeostasis is controlled by blood-brain barrier SLC7A5/LAT1 amino acid transporter.

Dolgodilina E, Imobersteg S, Laczko E, Welt T, Verrey F, Makrides V.

J Cereb Blood Flow Metab. 2016 Nov;36(11):1929-1941. Epub 2015 Oct 19.

3.

Genetic ablation of the p66Shc adaptor protein reverses cognitive deficits and improves mitochondrial function in an APP transgenic mouse model of Alzheimer's disease.

Derungs R, Camici GG, Spescha RD, Welt T, Tackenberg C, Späni C, Wirth F, Grimm A, Eckert A, Nitsch RM, Kulic L.

Mol Psychiatry. 2017 Apr;22(4):605-614. doi: 10.1038/mp.2016.112. Epub 2016 Jul 19.

PMID:
27431297
4.

High-speed video gait analysis reveals early and characteristic locomotor phenotypes in mouse models of neurodegenerative movement disorders.

Preisig DF, Kulic L, Krüger M, Wirth F, McAfoose J, Späni C, Gantenbein P, Derungs R, Nitsch RM, Welt T.

Behav Brain Res. 2016 Sep 15;311:340-353. doi: 10.1016/j.bbr.2016.04.044. Epub 2016 May 24.

PMID:
27233823
5.

Complex interplay between brain function and structure during cerebral amyloidosis in APP transgenic mouse strains revealed by multi-parametric MRI comparison.

Grandjean J, Derungs R, Kulic L, Welt T, Henkelman M, Nitsch RM, Rudin M.

Neuroimage. 2016 Jul 1;134:1-11. doi: 10.1016/j.neuroimage.2016.03.042. Epub 2016 Mar 24.

PMID:
27033685
6.

Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells.

Späni C, Suter T, Derungs R, Ferretti MT, Welt T, Wirth F, Gericke C, Nitsch RM, Kulic L.

Acta Neuropathol Commun. 2015 Nov 11;3:71. doi: 10.1186/s40478-015-0251-x.

7.

Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study.

Welt T, Kulic L, Hoey SE, McAfoose J, Späni C, Chadha AS, Fisher A, Nitsch RM.

J Alzheimers Dis. 2015;46(4):971-82. doi: 10.3233/JAD-150152.

PMID:
25881909
8.

Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease.

Hanenberg M, McAfoose J, Kulic L, Welt T, Wirth F, Parizek P, Strobel L, Cattepoel S, Späni C, Derungs R, Maier M, Plückthun A, Nitsch RM.

J Biol Chem. 2014 Sep 26;289(39):27080-9. doi: 10.1074/jbc.M114.564013. Epub 2014 Aug 12.

9.

Quantifying uncertainty in Transcranial Magnetic Stimulation - A high resolution simulation study in ICBM space.

Toschi N, Keck ME, Welt T, Guerrisi M.

Conf Proc IEEE Eng Med Biol Soc. 2012;2012:1218-21. doi: 10.1109/EMBC.2012.6346156.

PMID:
23366117
10.

Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation.

Kulic L, McAfoose J, Welt T, Tackenberg C, Späni C, Wirth F, Finder V, Konietzko U, Giese M, Eckert A, Noriaki K, Shimizu T, Murakami K, Irie K, Rasool S, Glabe C, Hock C, Nitsch RM.

Transl Psychiatry. 2012 Nov 13;2:e183. doi: 10.1038/tp.2012.109.

11.

Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice.

Santuccione AC, Merlini M, Shetty A, Tackenberg C, Bali J, Ferretti MT, McAfoose J, Kulic L, Bernreuther C, Welt T, Grimm J, Glatzel M, Rajendran L, Hock C, Nitsch RM.

Mol Psychiatry. 2013 Mar;18(3):358-68. doi: 10.1038/mp.2012.70. Epub 2012 Jun 12.

PMID:
22688190
12.

Consequences of chronic social stress on behaviour and vasopressin gene expression in the PVN of DBA/2OlaHsd mice--influence of treatment with the CRHR1-antagonist R121919/NBI 30775.

Erhardt A, Müller MB, Rödel A, Welt T, Ohl F, Holsboer F, Keck ME.

J Psychopharmacol. 2009 Jan;23(1):31-9. doi: 10.1177/0269881108089813. Epub 2008 May 30.

PMID:
18515457
13.

Transcranial magnetic stimulation in heterogeneous brain tissue: clinical impact on focality, reproducibility and true sham stimulation.

Toschi N, Welt T, Guerrisi M, Keck ME.

J Psychiatr Res. 2009 Jan;43(3):255-64. doi: 10.1016/j.jpsychires.2008.04.008. Epub 2008 Jun 2.

PMID:
18514227
14.

A reconstruction of the conductive phenomena elicited by transcranial magnetic stimulation in heterogeneous brain tissue.

Toschi N, Welt T, Guerrisi M, Keck ME.

Phys Med. 2008 Jun;24(2):80-6. doi: 10.1016/j.ejmp.2008.01.005. Epub 2008 Feb 25.

PMID:
18296093
15.
16.

Polymorphisms in the serotonin receptor gene HTR2A are associated with quantitative traits in panic disorder.

Unschuld PG, Ising M, Erhardt A, Lucae S, Kloiber S, Kohli M, Salyakina D, Welt T, Kern N, Lieb R, Uhr M, Binder EB, Müller-Myhsok B, Holsboer F, Keck ME.

Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):424-9.

PMID:
17440930
17.

Temazepam triggers the release of vasopressin into the rat hypothalamic paraventricular nucleus: novel insight into benzodiazepine action on hypothalamic-pituitary-adrenocortical system activity during stress.

Welt T, Engelmann M, Renner U, Erhardt A, Müller MB, Landgraf R, Holsboer F, Keck ME.

Neuropsychopharmacology. 2006 Dec;31(12):2573-9. Epub 2006 Jan 4.

18.

Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression-like behaviour: effects of chronic paroxetine treatment.

Keck ME, Sartori SB, Welt T, Müller MB, Ohl F, Holsboer F, Landgraf R, Singewald N.

J Neurochem. 2005 Mar;92(5):1170-9.

19.

Repetitive transcranial magnetic stimulation increases the release of dopamine in the nucleus accumbens shell of morphine-sensitized rats during abstinence.

Erhardt A, Sillaber I, Welt T, Müller MB, Singewald N, Keck ME.

Neuropsychopharmacology. 2004 Nov;29(11):2074-80.

20.
21.

Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model.

Keck ME, Welt T, Müller MB, Uhr M, Ohl F, Wigger A, Toschi N, Holsboer F, Landgraf R.

Neuropsychopharmacology. 2003 Feb;28(2):235-43. Epub 2002 Jul 25.

22.

Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis.

Czéh B, Welt T, Fischer AK, Erhardt A, Schmitt W, Müller MB, Toschi N, Fuchs E, Keck ME.

Biol Psychiatry. 2002 Dec 1;52(11):1057-65.

PMID:
12460689
23.

Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system.

Keck ME, Welt T, Müller MB, Erhardt A, Ohl F, Toschi N, Holsboer F, Sillaber I.

Neuropharmacology. 2002 Jul;43(1):101-9.

PMID:
12213264
24.

Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders.

Keck ME, Wigger A, Welt T, Müller MB, Gesing A, Reul JM, Holsboer F, Landgraf R, Neumann ID.

Neuropsychopharmacology. 2002 Jan;26(1):94-105.

25.

Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation in a psychopathological animal model are suggestive of antidepressant-like effects.

Keck ME, Welt T, Post A, Müller MB, Toschi N, Wigger A, Landgraf R, Holsboer F, Engelmann M.

Neuropsychopharmacology. 2001 Apr;24(4):337-49.

26.

The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats.

Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R.

Eur J Neurosci. 2001 Jan;13(2):373-80.

PMID:
11168542
27.

Acute transcranial magnetic stimulation of frontal brain regions selectively modulates the release of vasopressin, biogenic amines and amino acids in the rat brain.

Keck ME, Sillaber I, Ebner K, Welt T, Toschi N, Kaehler ST, Singewald N, Philippu A, Elbel GK, Wotjak CT, Holsboer F, Landgraf R, Engelmann M.

Eur J Neurosci. 2000 Oct;12(10):3713-20.

PMID:
11029641

Supplemental Content

Support Center